On 22 August 2014, orphan designation (EU/3/14/1324) was granted by the European Commission to DualTpharma B.V., the Netherlands, for 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethylsulfamide for the treatment of small cell lung cancer.
|Disease / condition||
Treatment of small cell lung cancer
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.